Misplaced Pages

Cirmtuzumab (also UC-961) is an anti-ROR1 humanised monoclonal antibody.

It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).

References

1. Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. (2015). "Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts". Blood. 126 (23): 1736. doi:10.1182/blood.V126.23.1736.1736.
2. "Researchers to test novel drug combination against toughest breast cancers". Medical Express. 2018-08-27.
3. Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
4. "1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo". Lymphoma News Today. 2018-05-18.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Monoclonal antibodies for tumors
• Antineoplastic and immunomodulating drug stubs